The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2021 | Impact of ide-cel and future directions
This year we saw the FDA approval of idecabtagene vicleucel (ide-cel; formerly bb2121) for the treatment of adult patients with relapsed or refractory multiple myeloma. In this video, Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, talks on the wider impact of this approval and where he believes ide-cel will move. Specifically discussed is the use of CAR-T in combination with other therapies, and the movement of CAR-T into earlier lines of treatment. This interview took place during the 2nd Immune Effector Cell Therapy in MM Workshop in Boston, MA.
